These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

137 related items for PubMed ID: 1325177

  • 1. Modulation by D,L-buthionine-S,R-sulphoximine of etoposide cytotoxicity on human non-small cell lung, ovarian and breast carcinoma cell lines.
    Mans DR, Schuurhuis GJ, Treskes M, Lafleur MV, Retèl J, Pinedo HM, Lankelma J.
    Eur J Cancer; 1992; 28A(8-9):1447-52. PubMed ID: 1325177
    [Abstract] [Full Text] [Related]

  • 2. Effect of buthionine sulfoximine on PtII and PtIV drug accumulation and the formation of glutathione conjugates in human ovarian-carcinoma cell lines.
    Mistry P, Loh SY, Kelland LR, Harrap KR.
    Int J Cancer; 1993 Nov 11; 55(5):848-56. PubMed ID: 8244583
    [Abstract] [Full Text] [Related]

  • 3. Buthionine sulphoximine-mediated sensitisation of etoposide-resistant human breast cancer MCF7 cells overexpressing the multidrug resistance-associated protein involves increased drug accumulation.
    Schneider E, Yamazaki H, Sinha BK, Cowan KH.
    Br J Cancer; 1995 Apr 11; 71(4):738-43. PubMed ID: 7710938
    [Abstract] [Full Text] [Related]

  • 4. Cytotoxicity of antitumor platinum complexes with L-buthionine-(R,S)-sulfoximine and/or etanidazole in human carcinoma cell lines sensitive and resistant to cisplatin.
    Brooks SE, Korbut TT, Dupuis NP, Holden SA, Teicher BA.
    Cancer Chemother Pharmacol; 1995 Apr 11; 36(5):431-8. PubMed ID: 7634385
    [Abstract] [Full Text] [Related]

  • 5. Effects of glutathione depletion using buthionine sulphoximine on the cytotoxicity in mammalian cells and human tumor cells in vitro.
    Jin YZ, Ding L, Shen ZF, Cai RM, Xu LM, Yang JK, Jin XQ, Lu WQ, Xu JF.
    Chin Med J (Engl); 1992 Aug 11; 105(8):647-50. PubMed ID: 1458967
    [Abstract] [Full Text] [Related]

  • 6. Glutathione depletion by L-buthionine sulfoximine antagonizes taxol cytotoxicity.
    Liebmann JE, Hahn SM, Cook JA, Lipschultz C, Mitchell JB, Kaufman DC.
    Cancer Res; 1993 May 01; 53(9):2066-70. PubMed ID: 8097674
    [Abstract] [Full Text] [Related]

  • 7. Enhanced melphalan cytotoxicity in human ovarian cancer in vitro and in tumor-bearing nude mice by buthionine sulfoximine depletion of glutathione.
    Ozols RF, Louie KG, Plowman J, Behrens BC, Fine RL, Dykes D, Hamilton TC.
    Biochem Pharmacol; 1987 Jan 01; 36(1):147-53. PubMed ID: 3801051
    [Abstract] [Full Text] [Related]

  • 8. Circumvention of drug resistance in cisplatin-resistant sublines of the human squamous carcinoma cell line HLac 79 in vitro and in vivo.
    Bier H.
    Acta Otolaryngol; 1991 Jan 01; 111(4):797-806. PubMed ID: 1950544
    [Abstract] [Full Text] [Related]

  • 9. Enhanced potentiation of cisplatin cytotoxicity in human ovarian carcinoma cells by prolonged glutathione depletion.
    Andrews PA, Schiefer MA, Murphy MP, Howell SB.
    Chem Biol Interact; 1988 Jan 01; 65(1):51-8. PubMed ID: 3345573
    [Abstract] [Full Text] [Related]

  • 10. The role of glutathione in resistance to cisplatin in a human small cell lung cancer cell line.
    Meijer C, Mulder NH, Hospers GA, Uges DR, de Vries EG.
    Br J Cancer; 1990 Jul 01; 62(1):72-7. PubMed ID: 2390486
    [Abstract] [Full Text] [Related]

  • 11. Potentiation of doxorubicin cytotoxicity by buthionine sulfoximine in multidrug-resistant human breast tumor cells.
    Dusre L, Mimnaugh EG, Myers CE, Sinha BK.
    Cancer Res; 1989 Feb 01; 49(3):511-5. PubMed ID: 2535960
    [Abstract] [Full Text] [Related]

  • 12. Exogenous glutathione attenuates the antiproliferative effect of buthionine sulfoximine.
    Kang YJ.
    Toxicology; 1994 Mar 11; 88(1-3):177-89. PubMed ID: 8160199
    [Abstract] [Full Text] [Related]

  • 13. P-glycoprotein and alterations in the glutathione/glutathione-peroxidase cycle underlie doxorubicin resistance in HL-60-R, a subclone of the HL-60 human leukemia cell line.
    Raghu G, Pierre-Jerome M, Dordal MS, Simonian P, Bauer KD, Winter JN.
    Int J Cancer; 1993 Mar 12; 53(5):804-11. PubMed ID: 8095491
    [Abstract] [Full Text] [Related]

  • 14. Augmentation of cisplatin (DDP) cytotoxicity in vivo by DL-buthionine sulfoximine (BSO) in DDP-sensitive and-resistant rat ovarian tumors and its relation to DNA interstrand cross links.
    Chen G, Zeller WJ.
    Anticancer Res; 1991 Mar 12; 11(6):2231-7. PubMed ID: 1776864
    [Abstract] [Full Text] [Related]

  • 15. Overcoming tumor necrosis factor-alpha resistance of human renal and ovarian carcinoma cells by combination treatment with buthionine sulfoximine and tumor necrosis factor-alpha. Role of tumor necrosis factor-alpha mRNA down-regulation in tumor cell sensitization.
    Mizutani Y, Yoshida O.
    Cancer; 1994 Feb 01; 73(3):730-7. PubMed ID: 8299097
    [Abstract] [Full Text] [Related]

  • 16. Buthionine sulfoximine enhances glutathione-but attenuates glutamate-stimulated cell proliferation.
    Kang YJ.
    Cell Mol Biol Res; 1995 Feb 01; 41(2):131-6. PubMed ID: 8581064
    [Abstract] [Full Text] [Related]

  • 17. Effects of buthionine sulfoximine treatment on cellular glutathione levels and cytotoxicities of cisplatin, carboplatin and radiation in human stomach and ovarian cancer cell lines.
    Lee KS, Kim HK, Moon HS, Hong YS, Kang JH, Kim DJ, Park JG.
    Korean J Intern Med; 1992 Jul 01; 7(2):111-7. PubMed ID: 1306072
    [Abstract] [Full Text] [Related]

  • 18. Selective and synergistic activity of L-S,R-buthionine sulfoximine on malignant melanoma is accompanied by decreased expression of glutathione-S-transferase.
    Fruehauf JP, Zonis S, al-Bassam M, Kyshtoobayeva A, Dasgupta C, Milovanovic T, Parker RJ, Buzaid AC.
    Pigment Cell Res; 1997 Aug 01; 10(4):236-49. PubMed ID: 9263331
    [Abstract] [Full Text] [Related]

  • 19. Augmentation of adriamycin, melphalan, and cisplatin cytotoxicity in drug-resistant and -sensitive human ovarian carcinoma cell lines by buthionine sulfoximine mediated glutathione depletion.
    Hamilton TC, Winker MA, Louie KG, Batist G, Behrens BC, Tsuruo T, Grotzinger KR, McKoy WM, Young RC, Ozols RF.
    Biochem Pharmacol; 1985 Jul 15; 34(14):2583-6. PubMed ID: 4040369
    [No Abstract] [Full Text] [Related]

  • 20. Cross-resistance and collateral sensitivity to natural product drugs in cisplatin-sensitive and -resistant rat lymphoma and human ovarian carcinoma cells.
    Parekh H, Simpkins H.
    Cancer Chemother Pharmacol; 1996 Jul 15; 37(5):457-62. PubMed ID: 8599869
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.